Table 2.
Acute and late gastrointestinal and genitourinary side effects reported in study for high-risk patients (n = 162).
| Side effects | WPRT + N-ADT (group A) n = 70 | PORT (group B) n = 92 | P* |
|---|---|---|---|
| Genitourinary acute | |||
| Grade 1 | 42 (60%) | 50 (55%) | .56 |
| Grade 2 | 17 (25%) | 18 (21%) | |
| Grade 3 | 2 (3%) | 3 (3%) | |
| Gastrointestinal acute | |||
| Grade 1 | 50 (71%) | 48 (52%) | .32 |
| Grade 2 | 25 (36%) | 41 (44%) | |
| Grade 3 | 45 (64%) | 51 (56%) | |
| Genitourinary late | |||
| Grade 1 | 19 (27%) | 38 (41%) | .088 |
| Grade 2 | 51 (73%) | 54 (59%) | |
| Grade 3 | 3 (%) | 3 (%) | |
| Gastrointestinal late | |||
| Grade 1 | 51 (71%) | 69 (52%) | .32 |
| Grade 2 | 5 (36%) | 5 (44%) | |
| Grade 3 | 2 (%) | 3 (%) |
WPRT: whole pelvic radiotherapy, PORT: prostate radiotherapy only.